ClinicalTrials.gg
Approved for marketingNCT03780127Updated Oct 24, 2023

ZX008 Expanded Access Protocol

An expanded access record providing Fenfluramine Hydrochloride in Dravet Syndrome, sponsored by Zogenix, Inc.. Approved for marketing. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
2 Years and older
Sex
All
01

Study summary

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.

Read the detailed description

The treatment plan consists of an up to 24-month Treatment Period. Access is via application by your health care provider and available at one of the Expanded Access treatment centers. The dose of ZX008 for the duration of the Treatment Period will range from 0.2 mg/kg/day to a maximum of 0.8 mg/kg/day, not to exceed a total daily dose of 30 mg/day; for patients concurrently being prescribed stiripentol, the maximum will be 0.5mg/kg/day, not to exceed a total daily dose of 20 mg/day.

The fenfluramine US Expanded Access Program (US EAP) is available to full-time US Residents only.

Participation in the US EAP is limited to patients currently residing in the US. Residency in the US must be for the duration of participation in the US EAP. Drug may not be shipped outside the US.

02

Conditions studied

  • Dravet Syndrome

Browse trials for

03

In context

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Lead sponsor

Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Zogenix, Inc. became part of UCB S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is male or female, age 2 years and older, inclusive as of Study Day 1.
  • Patient is diagnosed with Dravet syndrome.
  • Patient is experiencing convulsive seizures which are not controlled by current AEDs.
  • Patient is receiving at least one AED and will remain on at least one AED for the duration of treatment.
  • Patient has been approved for inclusion by Zogenix.

Exclusion criteria

Exclusion Criteria:

  • Patient requires or starts using an unacceptable or concomitant medication.
  • Patient has valvulopathy.
  • Patient is at risk for pulmonary hypertension.
  • Patient exclusion will be at the sole discretion of the Sponsor.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • DrugFenfluramineStudies of FenfluramineFenfluramine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.

    Also known as: ZX008

06

Where to request access

No study locations are listed for this record.

07

References and documents

Publications

  • Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, Schoonjans AS, Donner E, Wirrell E, Kothare S, Agarwal A, Lock M, Gammaitoni AR. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021 Dec;93:154-159. doi: 10.1016/j.seizure.2021.10.024. Epub 2021 Nov 2. PubMed 34768178 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03780127
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2018
Last update
Oct 24, 2023
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion